News & Updates

Extended clopidogrel monotherapy after DAPT reduces bleeding events in ‘bi-risk’ ACS patients

16 Sep 2023 by

Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.

Extended clopidogrel monotherapy after DAPT reduces bleeding events in ‘bi-risk’ ACS patients

16 Sep 2023

Common antihypertensive drug linked to glaucoma

15 Sep 2023 by

The use of calcium channel blockers (CCBs) may contribute to an increased risk of glaucoma despite CCBs having no effect on intraocular pressure (IOP), according to a large study.

Common antihypertensive drug linked to glaucoma

15 Sep 2023

COSMIC-313 highlights benefit of triplet regimen in RCC

15 Sep 2023 by

In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.

COSMIC-313 highlights benefit of triplet regimen in RCC

15 Sep 2023

COVID-19 booster may cause transient glycaemic elevations in T1D

15 Sep 2023

Individuals with type 1 diabetes (T1D) may experience mild, temporary glycaemic elevations following receipt of a COVID-19 booster vaccine, according to a study.

COVID-19 booster may cause transient glycaemic elevations in T1D

15 Sep 2023

Original New Drug Application Approvals by US FDA (01-15 September 2023)

15 Sep 2023

New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 September 2023)

15 Sep 2023

Mpox vax holds up against severe infection

14 Sep 2023 by

Individuals who have received mpox vaccination or have been previously exposed to mpox infection, which is used to be called monkeypox, appear to be better protected against severe disease from a subsequent infection, as shown in a study.

Mpox vax holds up against severe infection

14 Sep 2023

Oral antipsychotics show similar safety profile in older adults after major surgery

14 Sep 2023

Comparisons of atypical antipsychotics and haloperidol reveal similar rates of in-hospital adverse clinical events in older patients with postoperative delirium who have taken an oral low-to-moderate dose antipsychotic drug, a study has shown.

Oral antipsychotics show similar safety profile in older adults after major surgery

14 Sep 2023

Treating iron deficiency in heart failure provides some benefits

14 Sep 2023

Use of ferric carboxymaltose in patients who have heart failure with a reduced ejection fraction and iron deficiency appears to yield only numerical improvements the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance as compared with placebo, according to data from the HEART-FID trial.